Tin tức & Cập nhật

Adding anlotinib to gefitinib significantly improves progression-free survival (PFS) in treatment-naïve Chinese patients with EGFR-mutated (EGFRmut) advanced non-small-cell lung cancer (NSCLC), according to the results of the FL-ALTER phase III study.

Addition of daratumumab to the bortezomib, cyclophosphamide, and dexamethasone (VCD) regimen provides deeper haematological responses and improves progression-free survival (PFS) in patients with newly diagnosed myeloma who are not eligible for autologous stem cell transplantation (ASCT), according to the results of the AMaRC 03-16 phase II study.

For patients with severe alopecia areata who achieved meaningful hair regrowth with 1-year course of baricitinib, subsequent discontinuation appears to reverse treatment gains, highlighting the need for ongoing therapy.

Treatment with carboplatin-paclitaxel (CP) plus atezolizumab results in better quality-adjusted survival in patients with advanced or recurrent endometrial cancer (EC) as compared with CP alone, according to a post hoc analysis of the AtTEnd/ENGOT-EN7 trial.

In a systematic review and individual participant data (IPD) meta-analysis, the use of oral corticosteroids (OCS) improves short-term outcomes in children aged 12–71 months with acute preschool wheeze, more so among children with previous wheeze or asthma and those with moderate-to-severe acute wheeze.